NCT03763227View on ClinicalTrials.gov

Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy

PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

July 24, 2015

Primary Completion Date

August 29, 2019

Study Completion Date

August 29, 2019

Conditions
Retinal Dystrophies
Interventions
DRUG

Intravitreal ranibizumab (IVR) injection

Intravitreal ranibizumab (IVR) injection in patients with retinal dystrophy and macular cysts who have not responded to treatment with carbonic anhydrase inhibitors

DRUG

Carbonic Anhydrase Inhibitor (CAI) therapy

Carbonic anhydrase therapy (Oral or Topical) in patients with retinal dystrophy and macular cysts

All Listed Sponsors
lead

Sultan Qaboos University

OTHER

NCT03763227 - Intravitreal Ranibizumab (Lucentis®) in the Treatment of Non-leaking Macular Cysts in Retinal Dystrophy | Biotech Hunter | Biotech Hunter